Article
Dermatology
N. Onsun, B. Gunes, G. Kaya, Guckan B. Isik, Yabaci A. Tak
Summary: This study evaluates the long-term survival rates of adalimumab and infliximab based on real-life clinical data, and finds that the efficacy of these two drugs decreases over time.
Article
Dermatology
Gayle van der Kraaij, Celine Busard, Juul van den Reek, Stef Menting, Annelie Musters, Barbara Hutten, Menno de Rie, Wouter Ouwerkerk, Sun-Jine Van Bezooijen, Errol Prens, Theo Rispens, Annick de Vries, Elke de Jong, Wim de Kort, Jo Lambert, Martijn van Doorn, Phyllis Spuls
Summary: This study evaluated the efficacy, safety, and pharmacokinetic profile of adalimumab combined with methotrexate in the treatment of chronic plaque psoriasis. The results showed that combination therapy resulted in fewer patients showing antidrug antibodies and a trend towards improved treatment response.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Medicine, General & Internal
R. B. Warren, A. Blauvelt, J. Bagel, K. A. Papp, P. Yamauchi, A. Armstrong, R. G. Langley, V. Vanvoorden, D. De Cuyper, C. Cioffi, L. Peterson, N. Cross, K. Reich
Summary: The study found that bimekizumab was both noninferior and superior to adalimumab in reducing symptoms and signs of moderate-to-severe plaque psoriasis at week 16, but was associated with a higher frequency of oral candidiasis and diarrhea. Longer and larger trials are needed to further evaluate the efficacy and safety of bimekizumab compared to other agents in treating plaque psoriasis.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Ran Pan, Xiaolun Wang, Min Shu, Jaydeep Das, Manik Kalra, Zhidong Wang
Summary: The efficacy of SEC in the treatment of patients with moderate-to-severe plaque psoriasis is well demonstrated through NMA.
CHINESE MEDICAL JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Marika Cordaro, Rosalba Siracusa, Ramona D'Amico, Tiziana Genovese, Gianluca Franco, Ylenia Marino, Davide Di Paola, Salvatore Cuzzocrea, Daniela Impellizzeri, Rosanna Di Paola, Roberta Fusco
Summary: Infliximab was found effective in reducing pain sensitization in fibromyalgia, with decreased activation of microglia and astrocytes, and downregulation of the P2X7 receptor and p38-MAPK pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
T. Graier, W. Weger, C. Jonak, P. Sator, C. Zikeli, K. Prillinger, C. Sassmann, B. Gruber, W. Saxinger, G. Ratzinger, C. Painsi, A. Mlynek, N. Haering, B. Sadoghi, H. Trattner, R. Muellegger, F. Quehenberger, W. Salmhofer, Peter Wolf
Summary: In this study, the effectiveness and safety of IL-23p19 inhibitors in real-world patients were analyzed. Few differences in PASI improvement were detected among biologic-naive and biologic-non-naive patients treated with different IL-23p19 inhibitors after correction for previous biologic exposure. IL-23p19 inhibitors represent a promising treatment alternative for patients who have not responded to previous biologics.
SCIENTIFIC REPORTS
(2022)
Review
Immunology
Roberto Caporali, Yannick Allanore, Rieke Alten, Bernard Combe, Patrick Durez, Florenzo Iannone, Mike T. Nurmohamed, Sang Joon Lee, Taek Sang Kwon, Jean Soo Choi, Gahee Park, Dae Hyun Yoo
Summary: The study found that CT-P13 SC has more advantages compared to infliximab in treating patients with RA, demonstrating better efficacy and safety. Comparison with historical data also showed that CT-P13 SC has certain advantages over adalimumab/etanercept in terms of safety and efficacy.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2021)
Article
Dermatology
L. S. van der Schoot, J. J. Janssen, M. T. Bastiaens, A. de Boer-Brand, C. Christiaansen-Smit, D. N. H. Enomoto, R. Hovingh, R. A. Tupker, M. M. B. Seyger, L. M. Verhoef, J. M. P. A. van den Reek, E. M. G. J. de Jong
Summary: Implementation of protocolized biologic dose reduction can increase patient uptake of treatment, with additional staff support, extra consultation time, education for healthcare providers and patients, and effective tools such as a feasible protocol leading to more patients on biologic dose reduction.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Immunology
Audrey Paoletti, Bineta Ly, Samuel Bitoun, Gaetane Nocturne, Elodie Riviere, Jessica J. Manson, Andrea Matucci, Marc Pallardy, Niek De Vries, Xavier Mariette
Summary: This longitudinal study demonstrates that ADA but not ETA is able to restore the M2-like polarization of monocytes that is defective in RA.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
Lisa Schots, Rani Soenen, Brigitte Blanquart, Debby Thomas, Jo Lambert
Summary: This real-world study demonstrates that IL-17i are highly effective drugs for the treatment of psoriasis, with ixekizumab as the most effective biologic. Treatment modifications mainly occur in cases of inadequate response, primarily through switching medications and increasing doses, and least frequently in ixekizumab patients. Concentrations of the drug may rationalize clinical decision-making, but standardized algorithms are needed to validate its use.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Pharmacology & Pharmacy
Jill L. Kinzer, Troy A. Halseth, Jukyung Kang, Sang Yeop Kim, Preethi Kumaran, Michael Ford, Sergei Saveliev, St John Skilton, Anna Schwendeman
Summary: FDA-approved anti-TNF alpha biopharmaceuticals have been successful in treating autoimmune diseases, but there are product-specific differences in patient outcomes, possibly due to structural and functional differences. In this study, we compared the structural and functional differences among three anti-TNF alpha mAbs (Humira (R), Remicade (R), and Simponi Aria (R)) to understand their implications on efficacy.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Review
Chemistry, Medicinal
Xin Zhou, Zhuo Chen, Xinling Bi
Summary: Biologic drugs have revolutionized the treatment of psoriasis and rheumatological diseases, with biosimilar agents showing similar structure and function to originator products at a considerably lower cost. Approvals of adalimumab biosimilars by US FDA and EMA have expanded access to biologic therapies, with guidance on interchangeability and real-life practices still evolving.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Dermatology
Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek
Summary: This study investigated the changes in serum drug concentrations, anti-drug antibody (ADA) levels, and predictors for successful dose reduction of adalimumab, ustekinumab, and etanercept for psoriasis. The results suggest that interval prolongation for dose reduction may not increase immunogenicity in psoriasis patients with low disease activity.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Gastroenterology & Hepatology
Rachel Nice, Neil Chanchlani, Harry Green, Claire Bewshea, Tariq Ahmad, James R. Goodhand, Timothy J. McDonald, Mandy H. Perry, Nicholas A. Kennedy
Summary: This study validates the positivity thresholds for drug-tolerant anti-infliximab and -adalimumab antibody assays, and finds that low-concentration anti-drug antibodies were associated with lower drug levels and treatment failure, particularly for adalimumab. It highlights the importance of deriving antibody positivity thresholds for accurate detection and treatment outcomes.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Florian Rissel, Yoann Cazaubon, Syrine Saffar, Romain Altwegg, Melanie Artasone, Claire Lozano, Thierry Vincent, Alexandre Jentzer
Summary: Therapeutic drug monitoring (TDM) is important for the treatment of inflammatory diseases. In this study, we evaluated the performance of different assays for drug and antidrug antibodies (ADA) measurement. The results showed that the four immunoassays (Promonitor, i-Track10®, ez-Track1, and Lisa Tracker® ELISA) performed well in drug and ADA measurement.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Dermatology
Lisa A. Beck, Diamant Thaci, Mette Deleuran, Marjolein de Bruin-Weller, Zhen Chen, Faisal A. Khokhar, Meng Zhang, Zafer E. Ozturk, Brad Shumel
Summary: The study found that adults with moderate-to-severe AD treated with dupilumab for up to 3 years did not experience clinically significant changes in mean laboratory parameters, indicating that continuous long-term use of the treatment is supported without the need for laboratory monitoring.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Dermatology
D. Thaci, K. Eyerich, A. Pinter, M. Sebastian, K. Unnebrink, S. Rubant, D. A. Williams, P. Weisenseel
Summary: This study found that risankizumab was superior to FAEs in treating psoriasis, providing earlier and greater improvement in outcomes that persisted with continued treatment. Risankizumab also showed more favorable safety results with no new safety signals observed for either treatment arm.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Andrew Blauvelt, April W. Armstrong, Richard G. Langley, Kurt Gebauer, Diamant Thaci, Jerry Bagel, Lyn C. Guenther, Carle Paul, Bruce Randazzo, Susan Flavin, Ming-Chun Hsu, Yin You, Kristian Reich
Summary: In this study, guselkumab showed superior efficacy compared to secukinumab at week 48 in treating patients with moderate-to-severe plaque psoriasis, across various baseline characteristics. The largest differences in efficacy were observed in patients aged 65 and older, as well as in patients weighing over 100 kg.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Dermatology
Diamant Thaci, Ron Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B. Kimball
Summary: The clinical and health-related quality of life responses observed during the first 16 weeks of BE SURE were sustained over 2 years of treatment, regardless of bimekizumab maintenance dosing. Switching from adalimumab to bimekizumab also resulted in sustained improvements up to Week 104. Bimekizumab had a good safety profile with no new safety signals.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaci, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen
Summary: Baricitinib demonstrated a consistent safety profile in the long-term treatment of atopic dermatitis patients, with no new safety signals identified. The incidence rates of major adverse cardiovascular events, deep vein thromboses/pulmonary emboli, malignancies, and serious infections were within the ranges observed in the background population of patients with AD.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Medicine, General & Internal
Diamant Thaci, Dave Singh, Mark Lee, Helen Timmis, Dominique Jacobs, Paul Passier, Susanne Rohrer, Johan Beetens, De Phung, Eric Sondag, Goran Babic, Guido Wurth, Pia Kloepfer, Stefan Hartle, Silke Huttner
Summary: Four clinical studies investigated the safety, tolerability, efficacy, and pharmacokinetic profile of the anti-IL-17C monoclonal antibody MOR106 for the treatment of atopic dermatitis. The studies showed that MOR106 was well-tolerated but demonstrated ineffectiveness in treating AD. Further drug development in other indications is warranted due to its safety and pharmacokinetic characteristics.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Dermatology
Matthias Augustin, Andrea Bauer, Konstantin Ertner, Ralph von Kiedrowski, Florian Schenck, Jutta Ramaker-Brunke, Sophie Moeller, Anja Fait, Mike Bastian, Diamant Thaci
Summary: The PROLEAD study examined the effectiveness and safety of dupilumab in real-world clinical practice for patients with moderate-to-severe atopic dermatitis (AD). The results showed that dupilumab was more effective and well tolerated in a real-world setting compared to phase 3 clinical trials.
DERMATOLOGY AND THERAPY
(2023)
Review
Biology
Alin Codrut Nicolescu, Marius-Anton Ionescu, Maria Magdalena Constantin, Ioan Ancuta, Sinziana Ionescu, Elena Niculet, Alin Laurentiu Tatu, Henner Zirpel, Diamant Thaci
Summary: The severity evaluation of psoriasis in difficult-to-treat areas is a major challenge. There is controversy surrounding whether these areas should be evaluated differently. This review proposes solutions such as using special scores or adding correction factors to assess the severity of these areas within the existing scores.
Article
Dermatology
Mark G. Lebwohl, Joseph F. Merola, Katelyn Rowland, Megan Miller, Ya-Wen Yang, Jenny Yu, Yin You, Daphne Chan, Diamant Thaci, Richard G. Langley
Summary: This study evaluated the safety of guselkumab in 2891 patients with psoriasis who were treated for up to 5 years. The findings showed that guselkumab demonstrated favorable safety, consistent with previous reports. The safety event rates in guselkumab-treated patients were similar to those observed in the placebo group and remained consistent throughout long-term treatment.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Letter
Dermatology
Andrew Blauvelt, Diamant Thaci, Kim A. Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Daphne Chan, Jenny Yu, Ya-Wen Yang, Mark G. Lebwohl, Alice B. Gottlieb, Jeffrey Crowley, Peter Foley
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
A. D. Burden, Y. Okubo, M. Zheng, D. Thaci, P. van de Kerkhof, N. Hu, M. Quaresma, C. Thoma, S. E. Choon
Summary: Effisayil 1 was a study investigating the use of spesolimab in patients with a flare-up of generalized pustular psoriasis (GPP). The study found that patients receiving spesolimab showed rapid clearance of pustules and skin symptoms within 1 week. The effectiveness and safety of spesolimab were consistent across different patient demographic and clinical characteristics.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Dermatology
Nina Magnolo, Thomas Jaenicke, Athanasios Tsianakas, Wolfgang Czech, Diamant Thaci, Andreas Pinter, Delphine Kerob, Samir Salah, Thomas A. Luger
Summary: This study aimed to investigate the efficacy of skin care products containing emollients and a syndet with the ability to improve skin barrier and microbiome in moderate to severe AD patients. The results showed that patients using this product had significant improvements in itchiness and quality of life after 10 weeks, while using 23% less product compared to the control group.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Henning Olbrich, Christian D. Sadik, Ralf J. Ludwig, Diamant Thaci, Katharina Boch
Summary: Dupilumab, approved for atopic dermatitis and prurigo nodularis, has shown effectiveness in treating various dermatologic diseases including bullous autoimmune diseases, eczema, prurigo, and alopecia areata.
Correction
Rheumatology
Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaci, Thilo Klopsch, Anja Plenske, Lisa K. Blindzellner, Pascal Klaus, Thomas Meng, Peter-Andreas Loeschmann
RHEUMATOLOGY AND THERAPY
(2023)
Article
Oncology
Kim A. Papp, Mark G. Lebwohl, Diamant Thaci, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek C. Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Tina Pyo, Woori Ko
Summary: CT-P43 demonstrated equivalent efficacy to originator ustekinumab in adults with moderate to severe plaque psoriasis, with comparable pharmacokinetic, safety, and immunogenicity profiles.